These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26538622)

  • 21. Medulloblastoma: need for targeted treatment.
    Luttjeboer M; Kaspers GJ
    Expert Rev Anticancer Ther; 2006 May; 6(5):649-52. PubMed ID: 16759156
    [No Abstract]   [Full Text] [Related]  

  • 22. Vismodegib and Physeal Closure in a Pediatric Patient.
    Lucas JT; Wright KD
    Pediatr Blood Cancer; 2016 Nov; 63(11):2058. PubMed ID: 26864592
    [No Abstract]   [Full Text] [Related]  

  • 23. Insulin-like growth factor-I receptor - a potential therapeutic target in medulloblastomas.
    Reiss K
    Expert Opin Ther Targets; 2002 Oct; 6(5):539-44. PubMed ID: 12387677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medulloblastoma with extensive nodularity in nevoid basal cell carcinoma syndrome.
    Aliani S; Brunner J; Graf N; Altmeyer K; Niedermayer I; Strowitzki M
    Med Pediatr Oncol; 2003 Apr; 40(4):266-7. PubMed ID: 12555262
    [No Abstract]   [Full Text] [Related]  

  • 25. Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
    Roesler R; de Farias CB; Brunetto AT; Gregianin L; Jaeger M; Nör C; Thomaz A
    Neuro Oncol; 2022 Jul; 24(7):1210-1211. PubMed ID: 35552442
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances in molecular targets for the treatment of medulloblastomas.
    Ajeawung NF; Wang HY; Gould P; Kamnasaran D
    Clin Invest Med; 2012 Oct; 35(5):E246. PubMed ID: 23043706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A new drug for basal cell carcinoma].
    Witte F
    Schweiz Monatsschr Zahnmed; 2013; 123(12):1104-6. PubMed ID: 24730087
    [No Abstract]   [Full Text] [Related]  

  • 28. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts.
    Freeman CR; Taylor RE; Kortmann RD; Carrie C
    Med Pediatr Oncol; 2002 Aug; 39(2):99-108. PubMed ID: 12116057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
    Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
    Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
    Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
    Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular biology of medulloblastoma: will it ever make a difference to clinical management?
    Gilbertson RJ; Gajjar A
    J Neurooncol; 2005 Dec; 75(3):273-8. PubMed ID: 16195803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hedgehog hopes lifted by approval... and stung by failure.
    Allison M
    Nat Biotechnol; 2012 Mar; 30(3):203. PubMed ID: 22398601
    [No Abstract]   [Full Text] [Related]  

  • 34. [High risk cerebellar medulloblastoma: the use of high doses of chemotherapy].
    Benito Bernal A; Villa Alcázar M; Díaz Pérez MA; Madero López L
    An Esp Pediatr; 1997 Dec; 47(6):647-50. PubMed ID: 9575128
    [No Abstract]   [Full Text] [Related]  

  • 35. Medulloblastoma molecular dissection: the way toward targeted therapy.
    Remke M; Ramaswamy V; Taylor MD
    Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A functional genomics approach to identify pathways of drug resistance in medulloblastoma.
    Bertrand KC; Faria CC; Skowron P; Luck A; Garzia L; Wu X; Agnihotri S; Smith CA; Taylor MD; Mack SC; Rutka JT
    Acta Neuropathol Commun; 2018 Dec; 6(1):146. PubMed ID: 30591080
    [No Abstract]   [Full Text] [Related]  

  • 37. Do medulloblastoma tumors meet the Food and Drug Administration criteria for anti-erbB2 therapy with trastuzumab?
    Entz-Werle N; Velasco V; Neuville A; Geoerger B; Mathieu MC; Guerin E; Kehrli P; Gaub MP; Vassal G; Grill J
    Pediatr Blood Cancer; 2008 Jan; 50(1):163-6. PubMed ID: 16724315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene.
    Canettieri G; Di Marcotullio L; Coni S; Greco A; Gulino A
    Cell Cycle; 2010 Jun; 9(11):2047-8. PubMed ID: 20505339
    [No Abstract]   [Full Text] [Related]  

  • 39. High-dose chemotherapy for recurrent medulloblastoma: time for a reappraisal.
    Gajjar A
    Cancer; 2008 Apr; 112(8):1643-5. PubMed ID: 18306390
    [No Abstract]   [Full Text] [Related]  

  • 40. Interferon-gamma mediated up-regulation of caspase-8 sensitizes medulloblastoma cells to radio- and chemotherapy.
    Meister N; Shalaby T; von Bueren AO; Rivera P; Patti R; Oehler C; Pruschy M; Grotzer MA
    Eur J Cancer; 2007 Aug; 43(12):1833-41. PubMed ID: 17627812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.